<DOC>
	<DOC>NCT02290873</DOC>
	<brief_summary>A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open-label arm for midazolam, in patients undergoing a colonoscopy for diagnostic or therapeutic reasons.</brief_summary>
	<brief_title>A Phase III of Remimazolam in Patients Undergoing Colonoscopy</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>patients scheduled to undergo a colonoscopy. patients with known sensitivity to benzodiazepines, flumazenil, opioids, naloxone, or a medical condition such that these agents are contraindicated.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>